Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11431543 | 0.98 | HSD17B10 (0.47) | HSD17B10HDAC8KCNH2ACHETSHR | |
| Fluoride Ion SCHEMBL30331061 | 0.98 | HSD17B10 (0.47) | HSD17B10HDAC8KCNH2ACHETSHR | |
| SCHEMBL30212748 | 0.94 | HSD17B10 (0.45) | HSD17B10HDAC8KCNH2ACHETSHR | |
| SCHEMBL29251902 | 0.87 | HSD17B10 (0.41) | HSD17B10HDAC8KCNH2SMN1; SMN2 | |
| SCHEMBL29251900 | 0.87 | HSD17B10 (0.41) | HSD17B10HDAC8KCNH2ACHESMN1; SMN2 | |
| Acetic Acid SCHEMBL29252315 | 0.87 | HSD17B10 (0.41) | HSD17B10HDAC8 | |
| SCHEMBL29726482 | 0.87 | KCNH2 (0.52) | HSD17B10HDAC8KCNH2 | |
| SCHEMBL2938596 | 0.87 | KCNH2 (0.52) | HSD17B10HDAC8KCNH2 | |
| Hydrochloric Acid SCHEMBL326784 | 0.85 | KCNH2 (0.50) | HSD17B10HDAC8KCNH2 | |
| Hydrochloric Acid SCHEMBL30212931 | 0.85 | KCNH2 (0.50) | HSD17B10HDAC8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260140407-A1 | ELECTROCHROMIC SHEET AND ELECTROCHROMIC DEVICE | SUMITOMO BAKELITE CO., LTD. (JP) | 2026-05-21 | — | — | US | disclosed |
| US-20250208475-A1 | ELECTROCHROMIC SHEET, LENS FOR EYEGLASSES, AND EYEGLASSES | SUMITOMO BAKELITE CO., LTD. (JP) | 2025-06-26 | — | — | US | disclosed |
| CN-120153314-A | Electrochromic sheet and electrochromic device | 住友电木株式会社 | 2025-06-13 | — | — | CN | disclosed |
| CN-116829652-B | Liquid composition set, porous resin production device, and porous resin production method | 株式会社理光 | 2025-05-27 | — | — | CN | disclosed |
| CN-119998720-A | Electrochromic sheet, laminate, lens for spectacles, and spectacles | 住友电木株式会社 | 2025-05-13 | — | — | CN | disclosed |
| CN-118984969-A | Electrochromic sheet, eyeglass lens and eyeglass | 住友电木株式会社 | 2024-11-19 | — | — | CN | disclosed |
| US-20240231230-A1 | COMPOSITION FOR FORMING SILICON-CONTAINING RESIST UNDERLAYER FILM | NISSAN CHEMICAL CORPORATION (JP) | 2024-07-11 | — | — | US | disclosed |
| CN-111490230-B | Electrode, method for manufacturing the same, electrode element, and nonaqueous electrolyte electricity storage element | 株式会社理光 | 2024-05-07 | — | — | CN | disclosed |
| CN-112368284-B | Electrochromic compound, electrochromic composition and electrochromic element | 株式会社理光 | 2024-03-08 | — | — | CN | disclosed |
| US-20240069441-A1 | COMPOSITION FOR RESIST UNDERLYING FILM FORMATION | NISSAN CHEMICAL CORPORATION (JP) | 2024-02-29 | — | — | US | disclosed |
| US-7973030-B2 | Benzothiazepine and benzothiepine compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20110143149-A1 | RESIST UNDERLAYER FILM FORMING COMPOSITION CONTAINING SILICONE HAVING ONIUM GROUP | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-06-16 | — | — | US | disclosed |
| EP-1921125-B1 | Reversible recording material and displaying element | RICOH CO LTD (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-7803792-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-09-28 | — | — | US | disclosed |
| EP-1921125-A2 | Reversible recording material and displaying element | Ricoh Company, Ltd. (JP) | 2008-05-14 | — | — | EP | disclosed |
| US-7312208-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-20070203115-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1730157-A1 | IONIC LIQUIDS COMPRISING FLUORALKYLTRIFFLUOROBORATE ANIONS | MERCK PATENT GmbH (DE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005105815-A1 | IONIC LIQUIDS COMPRISING FLUORALKYLTRIFFLUOROBORATE ANIONS | MERCK PATENT GMBH (DE) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203115-A1 | Novel quaternary ammonium compounds | SLC10A2, SLC10A1, ABCB11 | HSD17B10 412/4885HDAC8 1484/4885KCNH2 818/4885 |
| US-20110143149-A1 | RESIST UNDERLAYER FILM FORMING COMPOSITION CONTAINING SILICONE HAVING ONIUM GROUP | SRR, KDM2B, MSR1 | HSD17B10 2244/4885HDAC8 2628/4885KCNH2 1014/4885 |
| US-20260140407-A1 | ELECTROCHROMIC SHEET AND ELECTROCHROMIC DEVICE | GJB2, LNPK, KCNN2 | HSD17B10 1697/4885HDAC8 4118/4885KCNH2 12/4885 |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | SLC10A1, GOT1, CES1 | HSD17B10 516/4885HDAC8 406/4885KCNH2 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.